6:02 AM ET
8-K
Capital Raise
Sagimet Biosciences Capital Raise of $115M
Sagimet Biosciences Inc. entered into an underwriting agreement for a public offering of 8,750,010 shares of Series A common stock at $10.00 per share and 2,750,010 pre-funded warrants at $9.9999 per share. The company expects to receive net proceeds of approximately $107.5 million, which will be used to fund a Phase 3 clinical trial for denifanstat in acne and other clinical development programs.
- Value
- $115M
- Counterparty
- Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC